Allergan and Sauders have been dreading the arrival of Evolus or another competitor. Well, the time is now. What kind of damage will Evolus do to Botox?
Does Saunders have a good plan in place for Jeuveau? Botox generates 23% of Allergan's revenue. Yes, Evolus isn't able to compete (just yet) in all the indications that Botox can. They will eventually. Cool Sculpting is slowing and I'm scared Botox is next? Layoffs to help the bottom line?
We know the price will be lower. If the data is equal then docs will make the switch. These are scary times for Allergan.